Preclinical developments in type 2 diabetes

Advanced Drug Delivery Reviews

Volumn 54, Issue 9, 2002, Pages 1199-1212

  Lenhard, James M ^a   Gottschalk, William K ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

ACC2; Acetyl CoA carboxylase 2; Dipeptidyl peptidase IV; DPP IV; GLP 1; Glucagon like peptide 1; I kappa kinase beta; IKK

Indexed keywords

GLUCOSE; INSULIN; MUSCLE;

CATABOLISM;

DRUG THERAPY;

3,3,14,14 TETRAMETHYLHEXADECANEDIOIC ACID; 5 TETRADECYLOXY 2 FUROIC ACID; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ACETYL COENZYME A; ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE 2; ACETYLSALICYLIC ACID; ADENYLATE KINASE; CARNITINE PALMITOYLTRANSFERASE; CITRIC ACID; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; EXENDIN 4; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; I KAPPA KINASE BETA; IBUPROFEN; ISOLEUCINE THIAZOLIDIDE; LIRAGLUTIDE; MALONYL COENZYME A; METFORMIN; NAPROXEN; PALMITOYL COENZYME A; PHOSPHOTRANSFERASE; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; GLUCAGON; I KAPPA B KINASE; PEPTIDE FRAGMENT; PROTEIN PRECURSOR; PROTEIN SERINE THREONINE KINASE;

CATABOLISM; COMORBIDITY; DEPRESSION; DIARRHEA; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG POTENCY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; GENE DELIVERY SYSTEM; GLUCONEOGENESIS; HEREDITY; HUMAN; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; NAUSEA; NIGHT SWEAT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; REVIEW; RHINOPHARYNGITIS; VERTIGO; VOMITING; ANIMAL; GLUCOSE BLOOD LEVEL; METABOLISM;

ACETYL-COA CARBOXYLASE; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; I-KAPPA B KINASE; INSULIN RESISTANCE; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 0037027299     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00092-3     Document Type: Review

References (99)

1. Chen K.-W., Boyko E.J., Bergstrom R.W., Leonetti D.L., Newell-Morris L., Wahl P.W., Fujimoto F.W. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of type 2 DM. Diabetes Care. 18:1995;747-753.
2. Haffner S.M., Miettinin H., Gaskill S.P., Stern M. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of type 2 DM in Mexican-Americans. Diabetes Care. 18:1995;1201-1207.
3. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose-fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1:1963;785-789.
4. Wieland O.H. The mammalian pyruvate dehydrogenase complex, structure and regulation. Rev. Physiol. Biochem. Pharmacol. 96:1983;123-170.
5. Lowry O.H., Passonneau J.V. Evidence for multiple binding sites on phosphofructokinase. J. Biol. Chem. 241:1966;2268-2279.
6. Boden G., Jadali F., White J., Liang Y., Mozzoli M., Chen X., Coleman E., Smith C. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J. Clin. Invest. 88:1991;960-966.
7. Boden G., Chen X., Ruiz J., White J.V., Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J. Clin. Invest. 93:1994;2438-2446.
8. Golay A., DeFronzo R.A., Ferrannini E., Simonson D.C., Thorin D., Acheson K., Thiebaud D., Curchod B., Jequier E., Felber J.P. Oxidative and non-oxidative glucose metabolism in non-obese Type 2 (non-insulin dependent) diabetic patients. Diabetologia. 31:1988;585-591.
9. Thorburn A.W., Gumbiner B., Bulacan F., Wallace P., Henry R.R. Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin dependent (Type II) diabetes independent of impaired glucose uptake. J. Clin. Invest. 85:1990;522-529.
10. Del Prato S., Bonadonna R.C., Bonora E., Gulli G., Solini A., Shank M., DeFronzo R.A. Characterization of cellular defects of insulin action in type 2 (non-insulin dependent) diabetes mellitus. J. Clin. Invest. 91:1993;484-494.
11. Rothman D.L., Magnusson I., Cline G.G.D., Kahn C.R., Shulman R.G., Shulman G.I. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin dependent diabetes mellitus. Proc. Natl. Acad. Sci. USA. 92:1995;983-987.
12. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104:1999;787-794.
13. Kelly D.E., Mandarino L.J. Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in non-insulin-dependent diabetes mellitus. J. Clin. Invest. 86:1990;1999-2007.
14. Boden G., Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin dependent diabetes. J. Clin. Invest. 96:1995;1261-1268.
15. Ruderman N.B., Saha A.K., Vavvas D., Witters L.A. Malonyl-CoA, fuel sensing and insulin resistance. Am. J. Physiol. 276:1999;E1-E18.
16. Pan D.A., Lillioja S., Kriketos A.D., Milner M.R., Baur L.A., Bogardus C., Jenkins A.B., Storlein L.H. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 46:1997;983-988.
17. Schmitz-Peiffer C., Oakes N.D., Browne C.L., Kraegen E.W., Biden T.J. Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat fed rat. Diabetes. 46:1997;169-178.
18. Schmitz-Peiffer C., Craig D.L., Biden T.J. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J. Biol. Chem. 274:1999;24202-24210.
19. Prentki M., Corkey B.E. Are the beta-cell signaling molecules malonyl-CoA and cytosolic long-chain acyl CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes. 45:1996;273-283.
20. Brownsey R.W., Denton R.M. Acetyl-coenzyme A carboxylase. Boyer P.D., Krebs E.G., The Enzymes. Vol. 18:1987;123-146 Academic Press, Miami.
21. Thampy K.G. Formation of malonyl coenzyme A in rat heart. J. Biol. Chem. 264:1989;17631-17634.
22. Bianchi A., Evans J.L., Iverson A.J., Nordlund A.-C., Watts T.D., Witters L.A. Identification of an isozymic form of acetyl CoA carboxylase. J. Biol. Chem. 265:1990;1502-1509.
23. Abu-Elheiga L., Almarza-Ortega D.B., Baldini A., Wakil S.J. Human acetyl-CoA carboxylase. J. Biol. Chem. 272:1997;10669-10677.
24. Ha J., Lee J.-K., Witters K.-S.K.L.A., Kim K.-H. Cloning of human acetyl-CoA carboxylase β and its unique features. Proc. Natl. Acad. Sci. USA. 93:1996;11466-11470.
25. Abu-Elheiga L., Brinkly W.R., Zhong L., Chirala S.S., Woldesgiorgis G., Wakil S.J. The subcellular localization of acetyl-CoA carboxylase 2. Proc. Natl. Acad. Sci. USA. 97:2000;1444-1449.
26. Wakil S.J., Stoops J.K., Joshi V.C. Fatty acid synthesis and its regulation. Annu. Rev. Biochem. 52:1983;537-579.
27. Hardie G. Fat and phosphorylation - the role of covalent enzyme modification in lipid synthesis. Trends Biochem. Sci. 6:1981;75-77.
28. Brownsey R.W., Denton R.M. Evidence that insulin activates fat-cell acetyl-CoA carboxylase by increased phosphorylation at a specific site. Biochem. J. 202:1982;77-86.
29. Witters L.A., Watts T.D., Daniels D.L., Evans J.L. Insulin stimulates the dephosphorylation and activation of acetyl-CoA carboxylase. Proc. Natl. Acad. Sci. USA. 85:1988;5473-5477.
30. Mabrouk G.M., Helmy I.M., Thampy K.G., Wakil S.J. Acute hormonal control of acetyl-CoA carboxylase. J. Biol. Chem. 265:1990;6330-6338.
31. Tepperman J., Tepperman H.M. The effects of antecedent food intake pattern on hepatic lipogenesis. Am. J. Physiol. 193:1958;55-64.
32. Lee J.-K., Kim K.-H. Roles of acetyl-CoA carboxylase β in muscle cell differentiation and in mitochondrial fatty acid oxidation. Biochem. Biophys. Res. Commun. 254:1999;657-660.
33. Kim J.M., Yoon M., Kang I., Kim S.S., Ha J. Evidence that acetyl-CoA carboxylase isoforms play different biological roles in H9c2 cardiomyocytes. Biochem. Biophys. Res. Commun. 248:1998;490-496.
34. Abu-Elheiga L., Matzuk M.M., Abo-Hashema K.A.H., Wakil S.J. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science. 291:2001;2613-2616.
35. Zhang S., Kim K.-H. Acetyl-CoA carboxylase is essential for nutrient-induced insulin secretion. Biochem. Biophys. Res. Commun. 229:1996;701-705.
36. Zhang S., Kim K.-H. Essential role of acetyl-CoA carboxylase in the glucose-induced insulin secretion in a pancreatic β-cell line. Cell. Signal. 10:1998;35-42.
37. Rose-Kahn G., Bar-Tana J. Inhibition of rat liver acetyl-CoA carboxylase by β,β′-tetramethyl-substituted hexadecanoic acid (MEDICA 16). Biochim. Biophys. Acta. 1042:1990;259-264.
38. McCune S.A., Harris R.A. Mechanism responsible for 5-(tetradecyloxy)-2-furoic acid inhibition of hepatic lipogenesis. J. Biol. Chem. 254:1979;10095-10101.
39. Maragoudakis M.E. Inhibition of hepatic acetyl coenzyme A carboxylase by hypolipidemic agents. J. Biol. Chem. 244:1969;5005-5013.
40. Kemel C., Casida J.E. Coenzyme A esters of 2-aryloxyphenoxypropionate herbicides and 2-arylpropionate anti-inflammatory drugs are potent and stereo-selective inhibitors of rat liver acetyl-CoA carboxylase. Life Sci. 50:1992;533-540.
41. Gronwald J.W. Herbicides inhibit acetyl-CoA carboxylase. Biochem. Soc. Trans. 22:1994;616-621.
42. Rose-Kahn G., Bar-Tana J. Inhibition of lipid synthesis by β,β′-tetramethyl-substituted, C14-C22, α,ω-dicarboxylic acids in cultured rat hepatocytes. J. Biol. Chem. 260:1985;8411-8415.
43. Pickup J.C., Crook M.A. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 41:1998;1241-1248.
44. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subacute inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study. Circulation. 102:2000;42-47.
45. Feldmann M., Maini R.N. Anti-TNFα therapy of rheumatoid arthritis: what have we learned. Annu. Rev. Immunol. 19:2001;163-196.
46. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:1993;87-91.
47. Hurel S., Ofei F., Wells A.N., Newkirk J., Sopwith M., Turnbull D., Taylor J. TNFα and insulin sensitivity in humans: effects in vivo of antibody blockade in obese NIDDM patients and in vitro upon human cultured myotubes. Exp. Clin. Endrocrinol. Diabetes. 104:(Suppl. 2):1996;59-60.
48. Hotamisligil G.S., Murray D.L., Choy L.N., Spiegelman B.M. Tumor necrosis factor α inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA. 91:1994;4854-4858.
49. Zhang B., Berger J., Hu E., Szalkowski D., White-Carrington S., Spiegelman B.M., Moller D.E. Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to the antiadipogenic effects of tumor necrosis factor-α Mol. Endocrinol. 10:1996;1457-1466.
50. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes. 43:1994;1271-1278.
51. Kim J.K., Kim Y.-J., Fillmore J.J., Chen Y., Moore I., Lee J., Yuan M., Li Z.W., Karin M., Perret P., Shoelson S.E., Shulman G.I. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 108:2001;437-446.
52. Ebstein W. Berlin Klin. Wochnschr. 13:1876;337.
53. Williamson R.T., Lond M.D. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br. Med. J. 1:1901;760-762.
54. Reid J., MacDougall A.I., Andrews M.M. Aspirin and diabetes mellitus. Br. Med. J. 2:1957;1071-1074.
55. Kopp E., Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 265:1994;956-959.
56. Yin M.-J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of the IκB kinase-β Nature. 396:1998;77-80.
57. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.-W., Karin M., Shoelson S.E. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ Science. 293:2001;1673-1677.
58. Nauck M. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol. 35:1998;117-129.
59. Drucker D.J. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr. Pharm. Des. 11:2001;1399-1412.
60. Scrocchi L., Brown T., MaClusky N., Brubaker P., Auerbach A., Joyner A., Drucker D. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2:1996;1254-1258.
61. MacLusky N., Cook S., Scrocchi L., Shin J., Kim J., Vaccarino F., Asa S., Drucker D. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology. 141:2000;752-762.
62. Larsen P., Fledelius C., Knudsen L., Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes. 50:2001;2530-2539.
63. Freyse E.J., Becher T., El-Hag O., Knospe S., Goke B., Fischer U. Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs. Diabetes. 46:1997;824-828.
64. Morales M., Lopez-Delgado M., Alcantara A., Luque M., Clemente F., Marquez L., Puente J., Vinambres C., Malaisse W., Villanueva-Penacarrillo M., Valverde I. Preserved GLP-I effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes. 46:1997;1264-1269.
65. Zhou J., Wang X., Pineyro M., Egan J. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes. 48:1999;2358-2366.
66. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 48:1999;2270-2276.
67. Perfetti R., Zhou J., Doyle M., Egan J. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 141:2000;4600-4605.
68. Tourrel C., Bailbe D., Meile M., Kergoat M., Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 50:2001;1562-1570.
69. Vella A., Shah P., Basu R., Basu A., Holst J., Rizza R. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 49:2000;611-617.
70. Vella A., Shah P., Basu R., Basu A., Camilleri M., Schwenk F., Holst J., Rizza R.A. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes. 50:2001;565-572.
71. Gutzwiller J., Drewe J., Goke B., Schmidt H., Rohrer B., Lareida J., Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 276:1999;R1541-R1544.
72. Juntti-Berggren L., Pigon J., Karpe F., Hamsten A., Gutniak M., Vignati L., Efendic S. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care. 19:1996;1200-1206.
73. Zander M., Taskiran M., Toft-Nielsen M., Madsbad S., Holst J. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care. 24:2001;720-725.
74. Larsen J., Hylleberg B., Ng K., Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care. 2001;1416-1421.
75. Gutniak M., Larsson H., Sanders S., Juneskans O., Holst J., Ahren B. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care. 20:1997;1874-1879.
76. Gutniak M., Larsson H., Heiber S., Juneskans O., Holst J., Ahren B. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care. 19:1996;843-848.
77. Burcelin R., Rolland E., Dolci W., Germain S., Carrel V., Thorens B. Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Ann. N.Y. Acad. Sci. 875:1999;277-285.
78. Baggio L., Adatia F., Bock T., Brubaker P.L., Drucker D.J. Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J. Biol. Chem. 275:2000;34471-34477.
79. Pauly R., Rosche F., Wermann M., McIntosh C., Pederson R., Demuth H. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach. J. Biol. Chem. 271:1996;23222-23229.
80. Holst J., Deacon C. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 47:1998;1663-1670.
81. Nagakura T., Yasuda N., Yamazaki K., Ikuta H., Yoshikawa S., Asano O., Tanaka I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem. Biophys. Res. Commun. 284:2001;501-506.
82. Marguet D., Baggio L., Kobayashi T., Bernard A., Pierres M., Nielsen P., Ribel U., Watanabe T., Drucker D., Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA. 97:2000;6874-6879.
83. Ahren B., Holst J., Martensson H., Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. 404:2000;239-245.
84. Balkan B., Kwasnik L., Miserendino R., Holst J., Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia. 42:1999;1324-1331.
85. Pauly R., Demuth H., Rosche F., Schmidt J., White H., Lynn F., McIntosh C., Pederson R. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism. 48:1999;385-389.
86. Pederson R., White H., Schlenzig D., Pauly R., McIntosh C., Demuth H. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 47:1998;1253-1258.
87. Wettergren A., Schjoldager B., Mortensen P., Myhre J., Christiansen J., Holst J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38:1993;665-673.
88. Eissele R., Goke R., Willemer S., Harthus H., Vermeer H., Arnold P., Goke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Invest. 22:1992;283-291.
89. Rothenberg P., Kalbag J., Smith H., Gingerich R., Nedelman J. Treatment with a DPP-IV inhibitor, NVP-DPP728, increases prandial intact GLP-1 levels and reduces glucose exposure in humans. Diabetes. 49:(Suppl. 1):2000;39.
90. Glund K., Hoffman T., Demuth H., Banke-Bochita J., Rost K., Fuder H. Single dose-escalation study to investigate the safety and tolerability of the DP IV inhibitor P32/98 in healthy volunteers. Diabetes. 49:(Suppl. 1):2000.
91. Demuth H., Hoffman T., Glund K., McIntosh C., Pederson R., Fuecker K., Fischer S., Hanefeld M. Single dose treatment of diabetic patients by the DP IV inhibitor P32/98. Diabetes. 49:(Suppl. 1):2000.
92. Ahrn B., Simonsson E., Efendic S., Eriksson J., Venholm P., Jansson P., Landin-Olsson M., Torgeirsson H., Rask E., Sandqvist M., Dickinson S., Holmes D. Inhibition of DPP-IV by NVP DPP728 improves metabolic control over a 4 week period in type 2 diabetes. Diabetes. 50:(Suppl. 1):2001;416.
93. De Meester I., Durinx C., Bal G., Proost P., Struyf S., Goossens F., Augustyns K., Scharpe S. Natural substrates of dipeptidyl peptidase IV. Adv. Exp. Med. Biol. 477:2000;67-87.
94. Nausch I., Mentlein R., Heymann E. The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta. Biol. Chem. Hoppe-Seyler. 371:1990;1113-1118.
95. Schiller L., Rivera L., Santangelo W., Little K., Fordtran J. Diagnostic value of fasting plasma peptide concentrations in patients with chronic diarrhea. Dig. Dis. Sci. 39:1994;2216-2222.
96. Lenhard J.M. PPAR gamma/RXR as a molecular target for diabetes. Receptors Channels. 7:2001;249-258.
97. Rose M., Paulik M., Lenhard J. Therapeutic approaches to non-insulin dependent diabetes mellitus. Exp. Opin. Ther. Patents. 9:1999;1223-1236.
98. Nielsen J., Galsgaard E., Moldrup A., Friedrichsen B., Billestrup N., Hansen J., Lee Y., Carlsson C. Regulation of beta-cell mass by hormones and growth factors. Diabetes. 50:(Suppl. 1):2001;S25-S29.
99. McCormack J., Westergaard N., Kristiansen M., Brand C., Lau J. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr. Pharm. Des. 7:2001;1451-1474.